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Abstract 
Aim: to compare the AgNOR's mean number with the histological type and grade of cerebral 
astrocytic tumors. 16 primary cerebral astrocytic tumors (4 diffuse astrocytomas, 4 anaplastic 
astrocytomas and 8 glioblastomas) stereotactic biopsied in the Department of Neurosurgery, 
Clinical Hospital „Prof. Dr. N. Oblu” Iaşi, and histopathologically conventional diagnosed in 
Department of Neuropathology of the same hospital, were retrospectively identified. Tumor 
specimens were submitted to a combined staining technique: one – step silver nitrate method 
for AgNOR protein sites (modified after Ploton et al, 1986) counterstained with periodic acid-
Schiff staining for basement membrane of vascular components. The mean AgNOR values 
(mAgNOR) for tumoral and vascular nuclei were determined. The average values of mean 
AgNORs/nucleus (mAgNOR/nucleus) presented a linear increase with increasing grade of 
malignancy from 1.96 for diffuse astrocytoma (GII), 2.34 for anaplastic astrocytoma (GIII), to 
3.18 for glioblastoma multiforme (GIV). mAgNOR/tumoral nucleus also showed a linear 
correlation with the histological tumor grade: 2.27 for diffuse astrocytomas, 2.78 for anaplastic 
astrocytomas, and 3.35 for glioblastomas multiforme. A distinct difference between the mean 
values of AgNORs/vascular nucleus was expressed: 1.52 for diffuse astrocytoma (GII), 1.90 for 
anaplastic astrocytoma (GIII), and 3.18 for glioblastoma multiforme (GIV). There were some 
overlaps between GIII and GIV astrocytic tumors regarding the mAgNOR/tumoral nucleus: 
maximum value in anaplastic astrocytomas (GIII) was 2.91 and minimum value in small cells 
glioblastomas (GIV) was 2.47. Differentiation could be achieved with mAgNORs/vascular 
nucleus as no extreme value overlapped: maximum value in anaplastic astrocytomas (GIII) was 
1.99 and minimum value in small cells glioblastomas (GIV) was 2.54. The malignancy grade of 
an  astrocytic tumor can accurately be establish both on histological features of the conventional 
stained  sample and on the average number, the shape and the distribution of AgNORs within 
tumoral and vascular nuclei, as AgNORs determinations supplement the histological 
information in small biopsies. 
Keywords: astrocytic tumor, nucleor organizer region, tumoral grade 
In the practice of neurooncology it is 
extremely important to know the 
histological grade of a brain tumor and 
particularly of an astrocytic neoplasia. 
Objective tumor growth potential is 
achieved today by immunohistochemical 
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methods, but there are many other cell 
cycle-associated molecules that are 
potential targets for histochemistry 
assessment of cell proliferation.  
The metaphase Nucleolar Organizer 
Regions (NORs) are chromosomal 
segments or loops (rDNA) containing 
ribosomal genes associated with proteins. 
These genes are clustered in 10 loci of the 
human acrocentric chromosomes 13, 14, 
15, 21, and 22. The transcriptional activity 
of these intranuclear segments plays a 
pivotal role in the formation of nucleoli, 
directing the syntesis of both ribosomes 
and associated proteins [5]. NORs 
associated protein [C23 (nucleolin) and 
B23 (nucleophosmin)] are selectively 
stained by silver impregnation technique 
in formalin-fixed paraffin-embedded 
tissues. After silver-staining, the NORs 
can be easily identified as black dots 
exclusively localized throughout the 
nucleolar area, and are called “AgNORs”. 
The expression of AgNOR proteins was 
associated with several biological 
properties of neoplastic cells: metabolic 
activity, DNA content, histological grade 
of differentiation and, especially, the 
rapidity of cellular proliferation [31, 7, 26, 
25]. 
The specific significance of AgNORs 
is not well understood. AgNOR 
quantification was used in tumor 
pathology as a parameter to distinguish 
malignant cells from benign or normal 
cells [11, 10, 9]. In the latest 20 years 
more than 400 studies was done in order 
to determine the correlation of AgNORs' 
quantity and quality with tumor 
aggressivness and rapidity of proliferation, 
with variable success rates that depended 
on tumor type [5]. A large number of 
papers have shown a linear correlation 
between AgNOR count and growth 
fraction in various human malignancies: 
breast cancers [32, 18], urinary bladder 
carcinoma [6], colorectal carcinoma [23], 
bone tumors [10], utererine cancer [12], 
endocrine cancers [22], skin cancers [2], 
lung cancers [28], brain cancers [8, 20]. 
Moreover, the method can be applied to 
small biopsies, can identify neoplastic 
clones with different proliferative 
activities and may stratify patients into 
different risk groups [25]. 
Because assessment of AgNORs offers 
an alternative approach to measure the 
tumor growth fraction and because there 
are a small number of articles dealing 
with AgNORs expression in astrocytic 
tumors, in this article we analyze possible 
correlation between AgNOR's 
morphology and AgNOR’s number with 
histological tumor grade in order to 
establish a possible role for it as an 
objective indicator of tumor biological 
behavior, just after the resection of a 
cerebral astrocytic neoplasia. 
Material and Methods 
Selection of cases 
16 primary cerebral astrocytic tumors 
stereotactic biopsied in the Department of 
Neurosurgery, Clinical Hospital „Prof. 
Dr. N. Oblu” Iaşi, and histopathologically 
diagnosed in Department of 
Neuropathology of the same hospital, 
were retrospectively identified. In all 
cases, tumor samples were fixed in 10% 
buffered formalin, included in paraffin, 
and stained with H&E according to 
standard procedure. 
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Table 1 
Histological subtypes and grade of 
malignancy of the 16 investigated 
astrocytomas 
Histological subtypes with 
grade of malignancy 
No. of 
cases 
Diffuse astrocytoma (grade II) 4 
Anaplastic astrocytoma (grade 
III) 
4 
Glioblastoma multiforme 
(grade IV) 
With small cells 
With giant cells 
8 
4 
4 
 
All 16 cases were histopathological 
diagnosed and graded according to the 
WHO Classification of Brain Tumors 
[19] and divided into groups (Table 1). 
There were 4 cases of diffuse astrocytoma 
- grade II (GII), 4 cases of anaplastic 
astrocytoma - grade III (GIII), and 8 cases 
of glioblastoma multiforme - grade IV 
(GIV). 
AgNOR Staining Technique  
Five µm thick paraffin sections, 
obtained from paraffin blocks with the 
most representative tumoral areas, were 
selected and submitted to a combined 
staining technique: one – step silver 
nitrate method for AgNOR protein sites 
(modified after Ploton et al, 1986) [27] 
counterstained with periodic acid-Schiff 
staining for basement membrane of 
vascular components.  
Briefly, slides were deparaffinized in 
xylene, and hydrated through descending 
concentrations of ethanol to double 
distilled, deionized water. The sections 
were stained with freshly prepared silver 
colloidal solution for 25 min in a 
thermostatically controlled environment 
(37oC). The working solution contained 
one volume of 2% gelatine in 1% aqueous 
formic acid and two volume of 50% 
aqueous silver nitrate solution. Sections 
were counterstained with periodic acid - 
Schiff solution, dehydrated through 
ascending grades of ethanol, cleared in 
xylene, and mounted in Canada balsam. 
Quantification of the number of 
AgNORs  
Histological sections, stained by the 
exposed method, were examined by eye, 
using in each case Olympus microscope, 
magnification 1000x, an oil-immersion 
lens, and cedarwood oil. In all cases we 
focused the image throughout the section 
thickness using at least 10 different 
microscopic fields in order to determine 
the homogeneous AgNOR quantitation 
throughout the tumor. Quantification of 
the AgNOR number has always been 
done in well preserved cells, excluding 
areas of tumoral necrosis, areas with 
staining artifacts or overlapping cells. We 
analysed the dense cellular areas and those 
with vessels that had maximal endothelial 
proliferation. Using the average formula 
we determined the mean AgNOR values 
for tumoral and vascular cells, taken 
individually and then together, for every 
histological subtype and then for every 
grade of malignancy. Mean number of 
AgNORs for each case was defined as the 
ratio between total number of black dots 
determinated in 100 individual tumor 
cells and the number of analysed cells. 
The same ratio was done for 100 
individual vascular cells. At each 
determinated black dot were noted the 
size (subjective quantified in: small, 
medium and large), the appearance 
(granular or homogeneous), and any 
other morphological features 
encountered. 
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Results 
The average values of mean 
AgNORs/nucleus (mAgNORs/nucleus) 
for each investigated tumor and its 
correlation with malignancy grades were 
represented in Table 2. Taking into 
account both tumoral and vascular cells, 
the mean values of mAgNORs/nucleus 
presented a linear increase with increasing 
grade of malignancy of cerebral 
astrocytomas from 1.96 for diffuse 
astrocytoma (GII), 2.34 for anaplastic 
astrocytoma (GIII), to 3.18 for 
glioblastoma multiforme (GIV). A distinct 
difference between the mean values of 
AgNORs/vascular nucleus was expressed: 
1.52 for diffuse astrocytoma (GII), 1.90 
for anaplastic astrocytoma (GIII), and 3.18 
for glioblastoma multiforme (GIV).  
The correlation between 
mAgNORs/tumoral nucleus and 
histological subtype of glioblastoma 
multiforme showed a distinct difference 
between small cells and giant cells 
variants, as giant cells glioblastoma 
expressed higher values (3.94) than small 
cells subtype (2.76). 
The differential diagnosis between 
anaplastic astrocytomas and small cells 
glioblastomas became very difficult to 
determine based only on 
mAgNORs/tumoral nucleus because the 
mean values are almost identical (2.78 
versus 2.76) as there were some overlaps 
of mAgNORs/tumoral nucleus between 
these two grades of malignancy: 
maximum value in anaplastic 
astrocytomas (GIII) was 2.91 and 
minimum value in small cells 
glioblastomas (GIV) was 2.47. 
Differentiation could be achieved by 
association of mAgNORs/vascular 
nucleus as there was no overlap between 
any investigated astrocytic tumor: 
maximum value in anaplastic 
astrocytomas (GIII) was 1.99 and 
minimum value in small cells 
glioblastomas (GIV) was 2.54 (Table 3). 
 
 
Figure 1 Diffuse astrocytoma (GII):  1 to 5 
small black dots in tumoral nuclei (silver 
impregnation method, magnification x1000) 
 
 
Figure 2 Glioblastoma multiforme (GIV):  
tumoral nuclei with 2 to 7 medium black dots 
scattered across nucleus area; one nucleus with 
bizarre great AgNOR dot (arrow) (silver 
impregnation method, magnification x1000) 
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Table 2 
Mean values of AgNORs in tumoral and vascular nuclei of cerebral astrocytomas 
according to their histological subtypes and malignancy grades 
AVERAGE  NUMBER OF AgNORs/NUCLEUS 
tumoral cells vascular cells Whole  tumor MALIGNANCY 
GRADE Range Group 
mean 
Range Group 
mean 
Range Group 
mean±S
D 
Diffuse astrocytoma 
(G II) 
2.14 
2.26 
2.31 
2.38 
 
 
2.27  
1.43 
1.45 
1.53 
1.54 
 
 
1.52 
1.78 
1.92 
1.96 
2.18 
 
 
1.96 
Anaplastic 
astrocytoma 
(G III) 
2.63 
2.74 
2.85 
2.91 
 
 
2.78 
1.82 
1.82 
1.98 
1.99 
 
 
1.90 
 
2.28 
2.30 
2.36 
2.42 
 
 
2.34 
Glioblastoma 
multiforme 
(G IV) 
2.47 
2.68 
2.79 
3.12 
3.76 
3.83 
4.02 
4.15 
 
 
 
3.35 
2.54 
2.72 
2.72 
3.60 
2.77 
2.86 
3.04 
4.00 
 
 
 
3.03 
2.50 
2.75 
2.92 
3.14 
3.34 
3.59 
3.39 
3.88 
 
 
 
3.18 
 
Table 3 
Differential diagnosis between glioblastoma multiforme and anaplastic astrocytoma 
based on mAgNOR/tumoral nucleus and mAgNOR/vascular nucleus 
HISTOLOGICAL SUBTYPE 
Anaplastic 
astrocytoma 
Small cells 
glioblastoma Giant cell glioblastoma 
NUMBER 
of AgNORs/ 
NUCLEUS 
Range Mean Range Mean Range Mean 
mAgNOR/ 
tumoral nucleus 
2.63 
2.74 
2.85 
2.91 
2.78 
 
2.47 
2.68 
2.79 
3.12 
2.76 
 
3.76 
3.83 
4.02 
4.15 
3.94 
 
mAgNOR/ 
vascular nucleus 
1.82 
1.82 
1.98 
1.99 
1.90 
2.54 
2.72 
2.72 
3.60 
2.895 
2.77 
2.86 
3.04 
4.00 
3.167 
 
 
 
 
 
Gabriela – Florenta Dumitrescu et al        Diagnostic in cerebral astrocytic tumors       69 
 
 
 
Table 4 
Comparison between average values of AgNORs /nucleus in the literature and in the 
present study 
MEAN NUMBER OF AgNORs/nucleus 
Diffuse astrocytoma 
(GII) 
Anaplastic astrocytoma 
(GIII) 
Glioblastoma multiforme 
(GIV) Author 
tumoral 
nucleus 
vascular 
nucleus nucleus 
tumoral 
nucleus 
vascular 
nucleus nucleus 
tumoral 
nucleus 
vascular 
nucleus nucleus 
Dumitrescu 
G. (2009) 
 
2,27 
 
 
1,52 
 
1,96 
 
2,78 
 
 
1,90 
 
2,34 
 
3,35 
 
 
3,03 
 
3,18 
Janczukowic
z J. (2003) 
[17] 
  1.65   2.11   2.55 
Choi YM et 
al. (1997) 
[4] 
  1.2 ±0.26   
1.90 
±0.64   
1.96± 
0.57 
Hara A. et al. 
(1991) [15] 
1,52±0,07 
 
1,80± 
0,13  
 
1,98± 
0,23 
 
2,87 ± 0,50  
 
2,05 ± 
0,29 
 
3,13 ± 1,13  
Tokunaga Y. 
et al. (1997) 
[30] 
  2.04± 0.54   
2.40±0.7
7   
2.71 ± 
1.13 
Haberland 
C. et al. 
(1996) [14] 
  1,73   2,81   4,56 
Tokiyoshi K. 
et al. (1992) 
[29] 
  1.68±0.87   
1,85±1.0
3   
2,76±1.2
6 
Pedal W.P. et 
al. (1994) 
[24] 
  1,98   2,84   
Small 
cells 
GM: 3.33
Giant 
cells 
GM: 4,24
 
Discussion 
Analysis of the AgNORs' mean 
number is a widely accepted method for 
diagnostic assessment of a wide range of 
tumors, both on histological and 
cytological preparations. In 1986, Ploton 
et al. [27] have used and improved the 
silver impregnation method brought in 
histopathological practice by Goodpasture 
and Bloom in 1975 [13]. Ploton et al. 
suggested that the number of 
AgNORs/cell correlates with cellular 
activity and may be an indicator of 
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malignancy, because a great number of 
AgNORs represents a more active 
proliferation, and thus a more malignant 
cell [27].  
AgNORs have found to be markers of 
proliferation in brain astrocytomas 
because from 1990 onwards some articles 
showed linear correlations between the 
number of AgNORs, Proliferating Cell 
Nuclear Antigen (PCNA), binding index 
of Ki-67, or mitotic rate and the 
histological grade [20, 3, 21, 17, 4].  
Several studies have been conducted on 
the possibility of discrimination between 
astrocytomas with low malignancy and 
those with high malignancy, using only 
the mean number of AgNOR dots per 
nucleus (mAgNOR/nucleus) [16]. 
The present study was designed to 
verify the usefulness of AgNORs 
determinations in discriminating 
histological malignancy grades of cerebral 
astrocytic tumors. We found a wide range 
of AgNORs values within each 
histological grade, probably reflecting that 
well known morphological heterogeneity 
and biological behaviour variations of 
cerebral astrocytic tumors. Nevertheless 
there was a linear correlation between 
mean values of AgNOR/nucleus and 
histological grade. 
Literature review on mean number of 
AgNORs in astrocytic tumors is 
summarized in Table 5 and data are 
compared with the results of the present 
study. It must be noted that the average 
values of AgNORs obtained in our study 
are in agreement with previous reports. 
All the authors obtained a gradual increase 
spectrum of the average number of 
AgNOR from diffuse astrocytomas, 
anaplastic astrocytoma, to glioblastomas 
multiforme and concluded that the 
number of AgNORs reflect the grade of 
malignancy in these neoplasias [17, 4, 15, 
30, 14, 29, 24]. 
Janczukowicz (2003) found a 
statistically significant relationship 
between histological grade and expression 
of AgNOR in astrocytic tumors, but he 
stressed the presence of a small 
overlapping of extreme values between 
astrocytomas GII and GIII and between 
GIII and GIV [17].  
We also observed a remarkable 
overlapping of the extreme values of the 
average number of AgNOR/tumoral 
nucleus between anaplastic astrocytomas 
(GIII) and small cells glioblastomas (GIV) 
probably because some of the anaplastic 
astrocytomas considered samples were in 
fact infiltration areas of a glioblastoma, 
the sample was too small and had no 
visible vessel or necrosis. Thus, AgNOR 
method may be particularly useful in 
small specimens or in biopsies from the 
infiltrating edge of an astrocytic tumor, 
where the usual histological features of 
malignancy may be absent. A further 
distinction between these two grades of 
malignancy could be made if 
mAgNOR/vascular nucleus is taken into 
account because none of the obtained 
values overlapped when comparing 
anaplastic astrocytomas with 
glioblastomas multiforme. 
Hara et al. (1991) calculated 
mAgNOR/vascular nucleus of 
astrocytomas grade II, III and IV 
(1.80±0.13, 2.87±0.50, and 3.13±1.13) 
and found it significantly higher  than that 
of vascular nucleus of normal brain 
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without neoplastic transformation (1.26 
± 0.05) [15]. It must be noted that in the 
present study we did not found such great 
values for mAgNOR/vascular nucleus in 
anaplastic astrocytoma, probably because 
Hara et al. used 1979 WHO Histological 
Typing of Brain Tumors and we used 
2000 WHO Brain Classification, where 
no vascular proliferation is needed to 
establish grade III of malignancy for these 
tumors. In the present study, the presence 
of increased average number of 
mAgNOR/vascular nucleus in anaplastic 
astrocytomas (GIII) and, especially, in 
glioblastomas multiforme (GIV) 
suggested that proliferative processes of 
tumor cells and vascular cells are 
interconnected. All these results showed 
that proliferative activity, both in tumoral 
cells and in vascular tumoral cells of the 
cerebral astrocytomas, increased with 
increasing grade of malignancy and 
therefore quantification of AgNORs is a 
useful marker in assessing the malignancy 
of these tumors. 
Conclusion 
A wide range of AgNOR values has 
been observed within each histological 
type and grade, probably reflecting 
variations in the biological behaviour. The 
number of AgNORs increased gradually 
from diffuse astrocytomas (GII) to 
anaplastic astrocytomas (GIII) and 
glioblastomas multiforme (GIV). Some 
overlaps of mAgNOR/tumoral nucleus 
have been detected between anaplastic 
astrocytomas (GIII) and glioblastomas 
multiforme (GIV) but the cause could be 
a wrong diagnostic of malignancy due to 
the small size of the stereotactic biopsies. 
The average number of 
mAgNORs/vascular nucleus appeared to 
be a more precious indicator as there was 
no overlap between any investigated 
astrocytic tumors. 
AgNOR method proved to be a useful 
method for histological grading as it 
supplemented the information obtained 
with conventional histological assessment. 
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